Related references
Note: Only part of the references are listed.How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease
Isaac Corro Ramos et al.
MEDICAL DECISION MAKING (2020)
The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature
Anees ur Rehman et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
Martine Hoogendoorn et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
Severity-Adjusted Probability of Being Cost Effective
Matthijs M. Versteegh et al.
PHARMACOECONOMICS (2019)
Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice
Tanja Fens et al.
VALUE IN HEALTH (2019)
The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization
Arja Viinanen et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine
Martine Hoogendoorn et al.
VALUE IN HEALTH (2019)
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
Jadwiga Wedzicha et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique
Ignacio Blanco et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study
Gunnar Johansson et al.
BMC PULMONARY MEDICINE (2018)
Economic burden of COPD in a Swedish cohort: the ARCTIC study
Karin Lisspers et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
Peter M. A. Calverley et al.
LANCET RESPIRATORY MEDICINE (2018)
Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis
Shih-Lung Cheng
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
Mohamed Ismail Abdul Aziz et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Estimating the effectiveness of pulmonary rehabilitation for COPD exacerbations: reduction of hospital inpatient days during the following year
Milla Katajisto et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2017)
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Jadwiga A. Wedzicha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands
Job F. M. van Boven et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via A Accuhaler® (ENERGITO® study)
Kai-Michael Beeh et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium plus olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy
Carl Selya-Hammer et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
UK-specific cost-effectiveness of tiotropium
Abigail Tebboth et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2016)
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)
Roland Buhl et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Tiotropium plus olodaterol shows clinically meaningful improvements in quality of life
Dave Singh et al.
RESPIRATORY MEDICINE (2015)
Primary-care-based episodes of care and their costs in a three-month follow-up in Finland
J. Heinonen et al.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE (2015)
Annual costs of chronic obstructive pulmonary disease in Finland during 1996-2006 and a prediction model for 2007-2030
Fredrik Herse et al.
NPJ PRIMARY CARE RESPIRATORY MEDICINE (2015)
Primary Care COPD Patients Compared with Large Pharmaceutically-Sponsored COPD Studies: An UNLOCK Validation Study
Annemarije L. Kruis et al.
PLOS ONE (2014)
Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease
Lydia Finney et al.
LANCET RESPIRATORY MEDICINE (2014)
Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD A Randomized Trial
Christopher B. Cooper et al.
CHEST (2013)
Tiotropium Respimat Inhaler and the Risk of Death in COPD
Robert A. Wise et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations
Pieter H. M. van Baal et al.
PHARMACOECONOMICS (2011)
COPD health care in Sweden - A study in primary and secondary care
Claes-Goran Lofdahl et al.
RESPIRATORY MEDICINE (2010)
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Process utility from providing informal care: the benefit of caring
WBF Brouwer et al.
HEALTH POLICY (2005)
Share Paper
